# üèõÔ∏è Asetria Writer - Architecture Summary

**Last Updated:** 2025-11-10 22:50 UTC  
**Version:** 2.0 (with Regulatory Data Agent)  
**Status:** Architecture Finalized

---

## üéØ Executive Summary

Asetria Writer ‚Äî —ç—Ç–æ **production-grade —Å–∏—Å—Ç–µ–º–∞ –≥–µ–Ω–µ—Ä–∞—Ü–∏–∏ —Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã—Ö –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤** (IB, Protocol, ICF, CSR) –Ω–∞ –æ—Å–Ω–æ–≤–µ multi-agent –∞—Ä—Ö–∏—Ç–µ–∫—Ç—É—Ä—ã —Å –∞–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∏–º –æ–±–æ–≥–∞—â–µ–Ω–∏–µ–º –¥–∞–Ω–Ω—ã—Ö –∏–∑ –ø—É–±–ª–∏—á–Ω—ã—Ö —Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã—Ö –∏—Å—Ç–æ—á–Ω–∏–∫–æ–≤.

**–ö–ª—é—á–µ–≤—ã–µ –æ—Å–æ–±–µ–Ω–Ω–æ—Å—Ç–∏:**
- 7 —Å–ø–µ—Ü–∏–∞–ª–∏–∑–∏—Ä–æ–≤–∞–Ω–Ω—ã—Ö –∞–≥–µ–Ω—Ç–æ–≤
- Dual-mode operation (Innovator/Generic/Hybrid)
- –ê–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–æ–µ –æ–±–æ–≥–∞—â–µ–Ω–∏–µ –¥–∞–Ω–Ω—ã—Ö –∏–∑ FDA, EMA, PubMed, ClinicalTrials.gov
- Template-driven generation (ICH/FDA compliant)
- Automated quality validation
- Professional export (DOCX/PDF)
- Full audit trail & provenance tracking

---

## üß© Multi-Agent Architecture (7 Agents)

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                         USER INPUT                              ‚îÇ
‚îÇ  Product Type: [Innovator] [Generic] [Hybrid]                  ‚îÇ
‚îÇ  Compound: Metformin HCl                                        ‚îÇ
‚îÇ  RLD: GLUCOPHAGE (NDA020357)                                    ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                     ‚îÇ
                     ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                   1. INTAKE AGENT                               ‚îÇ
‚îÇ  ‚Ä¢ Validate input                                               ‚îÇ
‚îÇ  ‚Ä¢ Determine mode (Innovator/Generic/Hybrid)                    ‚îÇ
‚îÇ  ‚Ä¢ Activate agent pipeline                                      ‚îÇ
‚îÇ  ‚Ä¢ Create project record                                        ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                     ‚îÇ
                     ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ            2. REGULATORY DATA AGENT ‚≠ê NEW                      ‚îÇ
‚îÇ  ‚Ä¢ Search external sources (FDA, EMA, PubMed, ClinicalTrials)  ‚îÇ
‚îÇ  ‚Ä¢ Extract & normalize data                                     ‚îÇ
‚îÇ  ‚Ä¢ Resolve conflicts & deduplicate                              ‚îÇ
‚îÇ  ‚Ä¢ Validate quality & calculate coverage                        ‚îÇ
‚îÇ  ‚Ä¢ Store in Regulatory Data Layer                               ‚îÇ
‚îÇ  ‚Ä¢ Return compound_data.json snapshot                           ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                     ‚îÇ
                     ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                   3. COMPOSER AGENT                             ‚îÇ
‚îÇ  ‚Ä¢ Select template (IB_Generic vs IB_Innovator)                 ‚îÇ
‚îÇ  ‚Ä¢ Build document structure                                     ‚îÇ
‚îÇ  ‚Ä¢ Determine data needs                                         ‚îÇ
‚îÇ  ‚Ä¢ Create placeholders                                          ‚îÇ
‚îÇ  ‚Ä¢ Generate document outline                                    ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                     ‚îÇ
                     ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                    4. WRITER AGENT                              ‚îÇ
‚îÇ  ‚Ä¢ Generate narrative per section                               ‚îÇ
‚îÇ  ‚Ä¢ Insert data from normalized layer                            ‚îÇ
‚îÇ  ‚Ä¢ Add cross-references                                         ‚îÇ
‚îÇ  ‚Ä¢ Format tables & figures                                      ‚îÇ
‚îÇ  ‚Ä¢ Apply writing style (formal/patient-friendly)                ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                     ‚îÇ
                     ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                  5. VALIDATOR AGENT                             ‚îÇ
‚îÇ  ‚Ä¢ Check ICH/FDA compliance                                     ‚îÇ
‚îÇ  ‚Ä¢ Verify data consistency                                      ‚îÇ
‚îÇ  ‚Ä¢ Validate references                                          ‚îÇ
‚îÇ  ‚Ä¢ Check RLD/TE-code (for Generic)                              ‚îÇ
‚îÇ  ‚Ä¢ Calculate quality score                                      ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                     ‚îÇ
                     ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                  6. ASSEMBLER AGENT                             ‚îÇ
‚îÇ  ‚Ä¢ Merge sections                                               ‚îÇ
‚îÇ  ‚Ä¢ Generate Table of Contents                                   ‚îÇ
‚îÇ  ‚Ä¢ Auto-number tables/figures                                   ‚îÇ
‚îÇ  ‚Ä¢ Resolve cross-references                                     ‚îÇ
‚îÇ  ‚Ä¢ Generate abbreviations list                                  ‚îÇ
‚îÇ  ‚Ä¢ Format references                                            ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                     ‚îÇ
                     ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                  7. REVIEWER AGENT                              ‚îÇ
‚îÇ  ‚Ä¢ Log human feedback                                           ‚îÇ
‚îÇ  ‚Ä¢ Track review comments                                        ‚îÇ
‚îÇ  ‚Ä¢ Trigger regeneration                                         ‚îÇ
‚îÇ  ‚Ä¢ Manage document versions                                     ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚î¨‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
                     ‚îÇ
                     ‚ñº
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ                      EXPORT                                     ‚îÇ
‚îÇ  ‚Ä¢ DOCX (house style)                                           ‚îÇ
‚îÇ  ‚Ä¢ PDF (from DOCX)                                              ‚îÇ
‚îÇ  ‚Ä¢ Bundle (sources.json + manifest.yaml)                        ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

---

## ‚≠ê Regulatory Data Agent (–ö–ª—é—á–µ–≤–æ–π –∫–æ–º–ø–æ–Ω–µ–Ω—Ç)

### –†–æ–ª—å
**"–ì–ª–∞–∑–∞ –∏ —Ä—É–∫–∏ —Å–∏—Å—Ç–µ–º—ã"** ‚Äî –µ–¥–∏–Ω—Å—Ç–≤–µ–Ω–Ω—ã–π –∞–≥–µ–Ω—Ç, –∫–æ—Ç–æ—Ä—ã–π —Ö–æ–¥–∏—Ç –Ω–∞—Ä—É–∂—É –∑–∞ –¥–∞–Ω–Ω—ã–º–∏.

### –ó–æ–Ω–∞ –æ—Ç–≤–µ—Ç—Å—Ç–≤–µ–Ω–Ω–æ—Å—Ç–∏
- –ü–æ–∏—Å–∫ –¥–∞–Ω–Ω—ã—Ö –≤ –ø—É–±–ª–∏—á–Ω—ã—Ö —Ä–µ–≥—É–ª—è—Ç–æ—Ä–Ω—ã—Ö –∏—Å—Ç–æ—á–Ω–∏–∫–∞—Ö
- –ò–∑–≤–ª–µ—á–µ–Ω–∏–µ –∏ –Ω–æ—Ä–º–∞–ª–∏–∑–∞—Ü–∏—è –¥–∞–Ω–Ω—ã—Ö
- –†–∞–∑—Ä–µ—à–µ–Ω–∏–µ –∫–æ–Ω—Ñ–ª–∏–∫—Ç–æ–≤ –º–µ–∂–¥—É –∏—Å—Ç–æ—á–Ω–∏–∫–∞–º–∏
- –í–∞–ª–∏–¥–∞—Ü–∏—è –∫–∞—á–µ—Å—Ç–≤–∞ –¥–∞–Ω–Ω—ã—Ö
- –ö—ç—à–∏—Ä–æ–≤–∞–Ω–∏–µ –∏ –≤–µ—Ä—Å–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–∏–µ
- –ü—Ä–æ–≤–µ–Ω–∞–Ω—Å-—Ç—Ä–µ–∫–∏–Ω–≥ (audit trail)

### –ö–æ–≥–¥–∞ –∞–∫—Ç–∏–≤–∏—Ä—É–µ—Ç—Å—è

| Product Type | Required? | Why |
|--------------|-----------|-----|
| **Innovator** | ‚ùå Optional | Sponsor provides all data |
| **Generic** | ‚úÖ **Mandatory** | Main source = public registries |
| **Hybrid** | ‚úÖ Partial | Nonclinical from registries, clinical from sponsor |
| **Post-marketing** | ‚úÖ Optional | Real-world data (FAERS, EudraVigilance) |

### Source Adapters (9 –∞–¥–∞–ø—Ç–µ—Ä–æ–≤)

1. **OpenFDA** ‚Üí Labels, adverse events
2. **Drugs@FDA** ‚Üí Approval documents, clinical/nonclinical summaries
3. **DailyMed** ‚Üí Current labels (conflict resolution: newer wins)
4. **EMA EPAR** ‚Üí European regulatory assessments
5. **ClinicalTrials.gov** ‚Üí Study designs, results
6. **PubChem** ‚Üí Chemical identifiers (inchikey), properties
7. **PubMed** ‚Üí Literature references
8. **FDA Orange Book** ‚Üí RLD, TE-codes (for generics)
9. **MHRA PAR** ‚Üí UK/EU regulatory data

### Data Flow

```
External Sources (FDA/EMA/PubMed/ClinicalTrials)
    ‚Üì
[Source Adapters] ‚Äî fetch raw data
    ‚Üì
[Normalizer] ‚Äî convert to standard schema
    ‚Üì
[Deduper & Resolver] ‚Äî remove conflicts, prioritize by source
    ‚Üì
[Data Validator] ‚Äî check quality, calculate coverage score
    ‚Üì
[Regulatory Data Layer] ‚Äî store in Postgres + Redis cache
    ‚Üì
[Snapshot API] ‚Äî serve compound_data.json to other agents
```

### API Endpoints

```
POST   /regdata/enrich              # Start data collection
GET    /regdata/snapshot/{inchikey} # Get normalized compound data
POST   /regdata/update/{source}     # Force update specific source
GET    /regdata/validate/{project}  # Get coverage & issues
GET    /regdata/resolve             # Resolve identifiers to inchikey
```

---

## üóÑÔ∏è Regulatory Data Layer

### Core Tables

```sql
-- Canonical compound identification
compounds (inchikey PK, name, mechanism, molecular_data, provenance)

-- Products (brands, generics)
products (id PK, inchikey FK, brand_name, application_number, rld, te_code)

-- Regulatory labels
labels (id PK, product_id FK, sections JSONB, effective_date, provenance)

-- Nonclinical data
nonclinical_summaries (id PK, inchikey FK, pk/tox/genotox JSONB, provenance)

-- Clinical data
clinical_summaries (id PK, inchikey FK, efficacy/safety JSONB, provenance)

-- Clinical trials
trials (nct_id PK, inchikey FK, design/outcomes JSONB, provenance)

-- Literature
literature (pmid PK, title, abstract, journal, provenance)

-- Adverse events (MedDRA normalized)
adverse_events (id PK, inchikey FK, soc, pt, incidence, provenance)

-- Audit trail
ingestion_logs, audit_changes
```

### Normalization Keys

- **Primary key:** `inchikey` (canonical compound identifier from PubChem)
- **Product key:** `application_number` + `region`
- **Provenance:** Every field tracks `source`, `url`, `retrieved_at`, `confidence`
- **Conflict resolution:** Priority by source type (label > EPAR > literature) + freshness

---

## üìã Data Contracts

### 1. labels.sections (FDA/EMA normalized)
```typescript
{
  label_meta: {source, application_number, effective_date, region},
  sections: {
    indications_and_usage,
    dosage_and_administration,
    contraindications,
    warnings_and_precautions,
    adverse_reactions_label,
    clinical_pharmacology: {mechanism, pharmacokinetics, pharmacodynamics}
  }
}
```

### 2. adverse_events (MedDRA normalized)
```typescript
{
  population: {study_id, arm, n, control_arm, n_control},
  events: [{soc, pt, incidence_pct, rr, ci95, serious, related, source}],
  summary: {any_teae_pct, treatment_related_pct, any_sae_pct}
}
```

### 3. clinical_pharmacology (PK/PD)
```typescript
{
  mechanism_of_action,
  pharmacokinetics: {bioavailability, tmax, t12, vss, clearance},
  pk_profiles: {study_id, arms: [{dose, cmax, auc, tmax}]},
  dose_response: {endpoint, model, parameters, data_points}
}
```

### 4. efficacy_data (Clinical outcomes)
```typescript
{
  clinical_summary: {efficacy: [{endpoint, delta, ci, p_value}]},
  trials: [{nct_id, phase, design, outcomes_primary, outcomes_secondary}]
}
```

---

## üé® Template System

### Template Engine: Handlebars

### Templates per Document Type

**IB (Investigator's Brochure):**
- `IB_Innovator_Template.hbs` (12 sections, full data)
- `IB_Generic_Template.hbs` (8 sections, bridge mode)

**Protocol:**
- `Protocol_Template.hbs` (16 sections)

**ICF (Informed Consent Form):**
- `ICF_Template.hbs` (12 sections, patient-friendly language)

**Synopsis:**
- `Synopsis_Template.hbs` (10 sections, tabular format)

### Template Features
- Conditional logic: `{{#if generic_mode}}`
- Data placeholders: `{{compound.name}}`
- Loops: `{{#each nonclinical.studies}}`
- Table specifications
- Reference markers

---

## ‚úÖ Validation & Quality Control

### Validation Rules (100+ rules)

**IB Innovator Checklist:**
- All 9 main sections present
- Nonclinical: PK, PD, Tox, Genotox, Carc, Repro
- Clinical: PK, PD, Efficacy, Safety
- At least 1 table per major section
- References ‚â• 15 entries
- Cross-references valid

**IB Generic Checklist:**
- RLD identified and referenced
- TE-code present (if FDA)
- Literature references ‚â• 10
- Bioequivalence section present
- No claim of original efficacy data
- Proper attribution to RLD

### Validation Output
```json
{
  "coverage": {"nonclinical": 0.82, "clinical": 0.91, "label": 1.0},
  "issues": [{"severity": "warn", "code": "MISSING_BE_REF"}],
  "score": 90
}
```

---

## üì¶ Export & Assembly

### Export Formats

**DOCX:**
- House style template (Asetria brand)
- Styles: Heading 1-4, Body, Table, Caption
- Auto-numbering for sections/tables/figures
- Header/footer with version info

**PDF:**
- From DOCX via LibreOffice headless
- Bookmarks for navigation
- Hyperlinked TOC and cross-references

### Bundle Structure
```
AST-256_IB_v1.0/
‚îú‚îÄ‚îÄ AST-256_IB_v1.0.docx
‚îú‚îÄ‚îÄ AST-256_IB_v1.0.pdf
‚îú‚îÄ‚îÄ sources.json          # All data sources used
‚îú‚îÄ‚îÄ manifest.yaml         # Metadata, versions, checksums
‚îú‚îÄ‚îÄ tables/
‚îÇ   ‚îú‚îÄ‚îÄ table_5.2-1.csv
‚îÇ   ‚îî‚îÄ‚îÄ table_6.1-1.csv
‚îú‚îÄ‚îÄ figures/
‚îÇ   ‚îî‚îÄ‚îÄ figure_7.1-1.png
‚îî‚îÄ‚îÄ references.bib        # Bibliography
```

### Manifest Format
```yaml
document:
  type: IB
  version: v1.0
  product_type: generic
  generated_at: 2025-11-10T22:00:00Z

agents:
  - Regulatory_Data_Agent v1.0.0
  - Composer_Generic v1.2.0
  - Writer_Generic v1.1.0

data_sources:
  - openFDA: NDA020357
  - EMA_EPAR: EU/1/00/000
  - PubMed: 15 articles

checksums:
  docx: sha256:abc123...
  pdf: sha256:def456...
```

---

## üîê Security & Compliance

### Data Access
- Egress allowlist –¥–ª—è –≤–Ω–µ—à–Ω–∏—Ö API
- –õ–æ–≥–∏ –±–µ–∑ PHI/PII
- MedDRA –ø–æ –ª–∏—Ü–µ–Ω–∑–∏–∏
- –¢–æ–ª—å–∫–æ public domain –¥–∞–Ω–Ω—ã–µ

### Audit Trail
- Provenance tracking –¥–ª—è –∫–∞–∂–¥–æ–≥–æ –ø–æ–ª—è
- –í–µ—Ä—Å–∏–æ–Ω–∏—Ä–æ–≤–∞–Ω–∏–µ –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤
- Change log –¥–ª—è –≤—Å–µ—Ö –ø—Ä–∞–≤–æ–∫
- Manifest —Å –∏—Å—Ç–æ—á–Ω–∏–∫–∞–º–∏ –∏ –≤–µ—Ä—Å–∏—è–º–∏

### RLS (Row Level Security)
- –í—Å–µ —Ç–∞–±–ª–∏—Ü—ã Supabase —Å RLS
- Service role —Ç–æ–ª—å–∫–æ –Ω–∞ backend
- User-level access control

---

## üìä Success Criteria (MVP)

### Technical
- ‚úÖ All 7 agents operational
- ‚úÖ Dual-mode (Innovator/Generic) working
- ‚úÖ External API enrichment functional
- ‚úÖ Template system with 15+ templates
- ‚úÖ DOCX/PDF export working
- ‚úÖ Validation score ‚â• 90 on test cases

### Business
- ‚úÖ Generate IB in < 30 minutes
- ‚úÖ 60-90 pages for IB (proper length)
- ‚úÖ ICH/FDA compliant structure
- ‚úÖ References auto-generated
- ‚úÖ First-pass acceptance ‚â• 80%

### User Experience
- ‚úÖ Simple project creation (5 fields)
- ‚úÖ Auto-enrichment (no manual data entry for generics)
- ‚úÖ Progress tracking (agent status)
- ‚úÖ Review interface (comments, edits)
- ‚úÖ One-click export (DOCX + PDF)

---

## üöÄ Implementation Timeline

**Phase 0:** Foundation & Architecture (Week 1-2)  
**Phase 1:** Data Layer & Schema (Week 2-4)  
**Phase 2:** External API Integration (Week 4-6) ‚Üê **Regulatory Data Agent**  
**Phase 3:** Multi-Agent System Core (Week 6-10)  
**Phase 4:** Document Templates (Week 10-14)  
**Phase 5:** Validation & QC (Week 14-16)  
**Phase 6:** Export Pipeline (Week 16-18)  
**Phase 7:** MVP Testing (Week 18-20)

**Total:** 20 weeks to MVP

---

## üìö Key Documents

1. **ASETRIA_WRITER_IMPLEMENTATION_PLAN.md** ‚Äî Master plan (20 weeks)
2. **REGULATORY_DATA_AGENT_SPEC.md** ‚Äî Technical spec for Regulatory Data Agent
3. **DATA_CONTRACTS_REGULATORY.md** ‚Äî Data contracts between agents
4. **IB_SECTION_TEMPLATES_EXAMPLES.md** ‚Äî Reference examples (submission-ready)
5. **WEEK_1_ACTION_PLAN.md** ‚Äî Detailed week 1 breakdown
6. **DOCUMENT_NUMBERING_GUIDE.md** ‚Äî ICH/FDA numbering standards

---

## üí° Key Insights

### 1. Data First, AI Second
- Normalized data layer = foundation
- LLM writes narrative around facts
- No hallucinations if data is structured

### 2. Regulatory Data Agent = Competitive Advantage
- Generic mode = 80% less data input
- External enrichment = automation
- Same pipeline, different templates

### 3. Provenance = Compliance
- Every field tracks source
- Audit trail for regulators
- Versioning for reproducibility

### 4. Quality by Validation
- Automated compliance checks
- Human review for final 10%
- Continuous improvement via feedback

---

**Status:** ‚úÖ Architecture Finalized

**Next:** Phase 0 Implementation (Week 1)

**Confidence:** High ‚Äî clear separation of concerns, well-defined contracts, proven approach
